TRMEDo — Thor Medical ASA Share Price
Last trade - 00:00- NOK688.61m
- NOK565.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.04 | ||
| Price to Tang. Book | 12.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.22% | ||
| Return on Equity | -13.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
Directors
- Jan Egberts NEC (62)
- Erik Skullerud CEO
- Malene Brondberg CFO (48)
- Sandra Jonsson COO
- Lars Nieba CTO (53)
- Jostein Dahle CSO (48)
- Gabriele Elbl VPR (59)
- Rosemarie Corrigan OTH (56)
- Pierre Dodion OTH (64)
- Per Samuelsson DRC (60)
- Jean-Pierre Bizzari IND (66)
- Rainer Boehm IND (60)
- Joanna Horobin IND (66)
- Karin Meyer IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 7th, 2009
- Public Since
- July 7th, 2014
- No. of Shareholders
- 14,060
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 280,492,395
- Address
- Karenslyst alle 9C, OSLO, 0278
- Web
- https://www.thormedical.no/
- Phone
- +47 22183301
- Contact
- Brede Ellingsaeter
- Auditors
- Ernst & Young AS
Upcoming Events for TRMEDo
Similar to TRMEDo
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 23:40 UTC, shares in Thor Medical ASA are trading at NOK2.92. This share price information is delayed by 15 minutes.
Shares in Thor Medical ASA last closed at NOK2.92 and the price had moved by +49.49% over the past 365 days. In terms of relative price strength the Thor Medical ASA share price has outperformed the FTSE Global All Cap Index by +45.75% over the past year.
The overall consensus recommendation for Thor Medical ASA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThor Medical ASA does not currently pay a dividend.
Thor Medical ASA does not currently pay a dividend.
Thor Medical ASA does not currently pay a dividend.
To buy shares in Thor Medical ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK2.92, shares in Thor Medical ASA had a market capitalisation of NOK688.61m.
Here are the trading details for Thor Medical ASA:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: TRMEDo
Based on an overall assessment of its quality, value and momentum Thor Medical ASA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Thor Medical ASA is NOK11.00. That is 277.36% above the last closing price of NOK2.92.
Analysts covering Thor Medical ASA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thor Medical ASA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +156.27%.
As of the last closing price of NOK2.92, shares in Thor Medical ASA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Thor Medical ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK2.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Thor Medical ASA's management team is headed by:
- Jan Egberts - NEC
- Erik Skullerud - CEO
- Malene Brondberg - CFO
- Sandra Jonsson - COO
- Lars Nieba - CTO
- Jostein Dahle - CSO
- Gabriele Elbl - VPR
- Rosemarie Corrigan - OTH
- Pierre Dodion - OTH
- Per Samuelsson - DRC
- Jean-Pierre Bizzari - IND
- Rainer Boehm - IND
- Joanna Horobin - IND
- Karin Meyer - IND